ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Gleevec (Imatinib Mesylate) is the first choice breakpoint cluster region (BCR)/ABL targeted oral therapy that produced a complete response almost in 71% to 80% of patients affected with CML.